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Objective: Repetitive upper extremity use in high-performance athletes is associated with the development of neurogenic
and vascular thoracic outlet syndrome (TOS). Surgical therapy in appropriately selected patients can provide relief of
symptoms and protection from future disability. We sought to determine the incidence and timing of competitive athletes
to return to their prior high-performance level after TOS treatment and surgery.
Methods: We reviewed all competitive high school, collegiate, and professional athletes treated for venous or neurogenic
TOS (nTOS) from 2000 to 2012. Patient demographics, workup, and treatment approaches were recorded and analyzed.
Patients with nTOS were assessed with quality of life surveys using the previously validated 11-item version of the
Disabilities of the Arm, Shoulder and Hand (QuickDASH) scale, scored from 0 to 100 (100 [ worse). Return to full
athletic activity was deﬁned as returning to prior competitive high school, collegiate, or professional sports.
Results: During the study period, 41 competitive athletes (44% female) with a mean age of 19 years, were treated,
comprising 13 baseball/softball players, 11 swimmers, 5 water polo players, 4 rowers, 2 volleyball players, 2 synchronized
swimmers, 1 wrestler, 1 diver, 1 weightlifter, and 1 football player. Twenty-seven athletes (66%) were treated for nTOS,
and 14 (34%) had Paget-Schroetter syndrome (PSS). All PSS patients underwent typical treatment of consisting of
thrombolysis/anticoagulation, followed by ﬁrst rib resection. Most nTOS patients were treated according to our previ-
ously reported highly selective algorithm, beginning with TOS-speciﬁc physical therapy (PT) after the clinical diagnosis
was made. Because of mild to modest symptom improvement after PT, 67% of the nTOS athletes evaluated ultimately
underwent supraclavicular ﬁrst rib resection and brachial plexus neurolysis. Return to full competitive athletics was ach-
ieved in 85% of all patients, including 93% of the PSS patients and 81% of the nTOS athletes, at an average of 4.6 months
after the intervention. In the nTOS cohort successfully returning to prior sports ability, seven (32%) were treated only with
PT. Of those athletes who underwent surgery for nTOS, 83% returned to full competitive levels. QuickDASH disability
scores improved from a mean of 40.4 preoperatively to 11.7 postoperatively, indicating signiﬁcant improvement in
symptoms after treatment. Recurrence of symptoms was noted in two nTOS (7%) and two PSS (14%) athletes.
Conclusions: Standardized treatment algorithms for venous and nTOS and aggressive TOS-speciﬁc PT are key compo-
nents to optimizing clinical outcomes in this special cohort of TOS patients. Most athletes treated for venous and nTOS
can successfully return to competitive sports at their prior high-performance level. (J Vasc Surg 2014;60:1012-8.)Thoracic outlet syndrome (TOS) typically presents as
upper extremity symptoms caused by compression of the
neurovascular structures in the area of the neck above the
ﬁrst rib. Clinical manifestations can include upper extremity
pain, paresthesias, numbness, weakness, fatigability,
swelling, discoloration, and Raynaud phenomenon. TOS
may result from a variety of anomalies, including cervical
ribs, fascial bands, and abnormalities of the origin or inser-
tion of the anterior or middle scalene muscles.1 Repetitive
upper extremity use, as can be seen in high-performance
overhead athletes, can be associated with the development
of vacular TOS and neurogenic TOS (nTOS).
Symptoms from nTOS are due to compression, irrita-
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2plexus, speciﬁcally within the scalene triangle at the base of
the neck or within the subpectoral space immediately
inferolateral to the clavicle, or both. Repetitive overhead
motions and exercise exhibited by athletes may lead to
loss of shoulder girdle stability and hypertrophy or imbal-
ance of the anterior/middle scalene muscles or pectoralis
minor muscle, or both, all of which contribute to the devel-
opment of nTOS. Athletes might be at even higher risk
given the relative amount of musculature developed in
training.
Vascular TOS can involve the subclavian artery or vein,
although much less common than nTOS. Arterial TOS,
which is incredibly rare, can cause subclavian artery aneu-
rysm with associated thrombus and distal embolization.2,3
Chronic injury and compression of the subclavian vein be-
tween the clavicle and ﬁrst rib and nearby subclavius
tendon increases the risk of effort thrombosis, also known
as Paget-Schroetter syndrome (PSS). PSS is also a relatively
uncommon condition, far less common than nTOS, but is
described more frequently in young competitive athletes.4,5
Competitive athletes comprise a distinct patient popu-
lation that has not only a higher predisposition to the
development of TOS but also high physical performance
demands and substantial pressures to achieve a rapid return
to previous levels of physical performance after being
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TOS treatment and possible surgery can have a signiﬁcant
effect in their overall performance abilities, and little has
been published speciﬁcally about the ability of athletes to
recover after TOS. The purpose of this study was to eval-
uate the ability and timing of competitive athletes to return
to their prior high-performance level after TOS treatment
and surgery.
METHODS
We reviewed all competitive athletes treated at our
institution for vascular or nTOS from 2000 to 2013.
Approval for the project was obtained from our Institu-
tional Review Board and informed consent was obtained
for all patients. Competitive athletes at the time of presen-
tation were deﬁned by active participation in organized in-
dividual or team sports at the varsity high school, National
Collegiate Athletic Association (NCAA) collegiate, or pro-
fessional or semi-professional levels, as reported by the pa-
tients and veriﬁed by team records or discussions with
coaches. The study excluded recreational athletes evaluated
for TOS at our institution.
All athletes referred for evaluation of nTOS from 2000
to 2007 ultimately underwent surgery and were included in
the analysis. Most patients exhibited typical upper extrem-
ity discomfort, paresthesias, and symptomatology, and dur-
ing this earlier period were offered surgical decompression
if results of electromyelography studies, orthopedic evalua-
tion, and spine evaluation were indicative of nTOS.
Since 2007, we have implemented a prospective highly
selective treatment algorithm, previously published,6 that
uses response to TOS-speciﬁc physical therapy (PT) as a
main predictor of surgical success. Athletes evaluated
from 2007 to 2013 were included in this current analysis.
This treatment algorithm included documentation of qual-
ity of life scores using the validated 11-item version of the
Disabilities of Arm, Shoulder and Hand (QuickDASH)
questionnaire (QD), which is scored from 0 to 100
(100 ¼ worse), duplex imaging of the thoracic outlet,
and mandatory TOS-speciﬁc PT designed to mimic relaxa-
tion of the thoracic outlet.7-9 The QD scale is a validated
survey speciﬁcally designed to measure physical function
and disability in persons with musculoskeletal disorders of
the upper limb. In addition, it has a module focused specif-
ically on high-level performance for athletes or performing
artists, with questions documenting the degree of disability
associated with their particular sport or activity.8
Patients since 2007 were then offered decompressive
surgery based on some response to PT and improvement
in symptoms, and those with no response or worsening
symptoms with this speciﬁc PT were believed to have other
syndromes and not likely to improve with TOS surgery. All
nTOS patients offered surgery underwent a standardized
supraclavicular approach to decompression, anterior and
middle scalenectomy, complete rib resection, and extensive
brachial plexus neurolysis.
Vascular TOS patients treated from 2000 to 2013 were
also identiﬁed and included in this study. No competitiveathletes with arterial TOS were found during the study
period, and therefore, all athletes with vascular TOS pre-
sented with effort thrombosis. PSS athletes were most
often treated with thrombolysis before surgical decompres-
sion of the thoracic outlet, along with adjunct venoplasty at
the time of rib resection or after, depending on recurrent
symptoms. No open venous reconstructions were per-
formed, although extensive venolysis was used to free up
external scar tissue. All PSS patients underwent an infracla-
vicular, supraclavicular, or paraclavicular approach to
decompression based on muscular bulk and to safely visu-
alize the injured vein and subclavius tendon.
Detailed information for each patient was summarized
from the electronic medical record review. All athletes were
also contacted by phone or e-mail in the summer of 2013
and asked to participate in a follow-up survey, which
included questions about timing and degree of return to
competitive sport, current and previous symptoms, and
most recent QD scores.
The primary outcome measure was return to full ath-
letic activity, deﬁned as competing postoperatively to the
prior level of high school, collegiate, or professional sports.
The duration of recovery, incidence of recurrence, and
complications were also recorded and analyzed. Data
were collected and statistical analyses performed using
Excel 2010 software (Microsoft Corp, Redmond, Wash).
Paired t-tests were used to determine differences between
the QD disability scores before and after PT, as well as pre-
operatively and postoperatively. The Wilcoxon rank sum
test or Fisher exact test were used to test for statistical dif-
ferences between groups, where appropriate, with values of
P < .05 considered signiﬁcant.RESULTS
During the study period, 41 competitive athletes un-
derwent evaluation or surgical treatment for all forms of
TOS; of those, 66% were nTOS patients and 34% were
PSS patients. Demographic information is reported in
Table I, with the athlete cohort consisting of 23 male
(56%) and 18 female (44%) athletes, with a mean age of
19 years (range, 13-36 years). Seven patients (17%) were
professional athletes, 16 (39%) participated in collegiate
sports, and 18 (44%) participated on high school teams
(Fig 1). The patients participated in the following sports:
baseball, 13; swimming, 11; water polo, 5, rowing, 4;
volleyball, 2; synchronized swimming, 2; wrestling, 1; div-
ing, 1, and football, 1. Patients being evaluated for nTOS
exhibited pre-evaluation symptoms for a mean of
11 months, whereas PSS athletes were sidelined from their
sport for a mean of 1.6 months before surgical evaluation.
nTOS patients. Treatments and clinical outcomes for
27 athletes with nTOS are reported in Table II. Nine
(33%) were treated nonoperatively with only TOS-speciﬁc
PT, and 18 (67%) underwent operative decompression.
There was no predilection towards the right or left arm,
and also none to the dominant arm. Postoperative com-
plications included one hemothorax requiring video-assisted
Fig 1. Distribution of athletes treated for neurogenic thoracic
outlet syndrome (nTOS) and Paget-Schroetter syndrome (PSS).
Table I. Demographics of competitive athletes with
neurogenic thoracic outlet syndrome (nTOS) and Paget-
Schroetter syndrome (PSS)
Variablea
All
(N ¼ 41)
nTOS
(n ¼ 27)
PSS
(n ¼ 14)
Age, years 19.0 (13-36) 19.0 (14-32) 18.8 (15-24)
Female 18 (44) 17 (63) 1 (7)
Sport
Swimming 11 (27) 11 (41) 0 (0)
Baseball 13 (33) 4 (14) 9 (65)
Synchronized
swimming
2 (5) 2 (7) 0 (0)
Volleyball 2 (5) 1 (4) 1 (7)
Rowing 4 (10) 3 (11) 1 (7)
Football 1 (2) 0 (0) 1 (7)
Water polo 5 (12) 3 (11) 2 (14)
Weightlifting 1 (2) 1 (4) 0 (0)
Wrestling 1 (2) 1 (4) 0 (0)
Diving 1 (2) 1 (4) 0 (0)
Affected side right 26 (63) 14 (52) 12 (86)
Affected side dominant 28 (68) 16 (59) 12 (86)
Bilateral 1 (2) 1 (4) 0 (0)
aContinuous data are presented as the mean (range) and categoric data as
number (%).
Table II. Treatment type and outcomes for competitive
athletes with neurogenic thoracic outlet syndrome
(nTOS) and Paget-Schroetter syndrome (PSS)
Variablea
All
(N ¼ 41)
nTOS
(n ¼ 27)
PSS
(n ¼ 14)
Treatment
Operative 32 (78) 18 (67) 14 (100)
Nonoperative 9 (22) 9 (33) 0 (0)
Hospital stay, days 2.6 (1-12) 1.9 (1-6) 3.5 (1-12)
QD score
Preoperative 40.4 40.4 e
Postoperative 11.7 11.7 e
Thrombolysis timing
before surgery, days
84 (2-730) e 84 (2-730)
Return to full sport 35 (85) 22 (82) 13 (93)
Time to pain free, months 2.7 (1-12) 3.4 (1-12) 1.9 (2-12)
Time to return to full
sport, months
4.6 (1.5-12) 4.4 (1.5-6) 4.7 (2-12)
Post-op anticoagulation
duration, months
2.3 (1-5) e 2.3 (1-5)
QD, QuickDASH (11-item version of the Disabilities of Arm, Shoulder and
Hand assessment).
aContinuous data are presented as the mean (range) and categoric data as
number (%).
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lothorax requiring drainage, and one wound seroma.
Most patients undergoing operation stayed overnight
and rapidly began postoperative PT consisting of range of
motion and strengthening exercises. Trainers and physical
therapists were instructed to gradually build up strength
and range of motion in the immediate postoperative period
and allow return to full use of the upper extremity at the
6-week to 8-week follow-up. The nTOS athletes were side-
lined from their sport for an average of 11 months beforesurgical decompression and for 4.6 months after surgical
decompression.
The QD scores were obtained prospectively for 70%
patients preoperatively and improved signiﬁcantly, from
40.4 preoperatively to 11.7 postoperatively (P ¼ .02),
and had improved even more, to 6.8, at latest phone survey
follow-up (mean follow-up, 37 months; range, 3-
123 months; P ¼ .02 compared with baseline; Fig 2).
In the nine patients who underwent TOS-speciﬁc PT
only and ultimately did not have surgery, the baseline QD
score was 37.4 and improved slightly to 30.3 after PT
(P ¼ .14). By following our algorithm with slight improve-
ment, they were all offered decompression but chose, due
to a variety of scheduling reasons (most often due to aca-
demic conﬂicts or scholarship requirements), to continue
with PT or attempt to return to sport. At the latest survey
follow-up, this “nonoperative” athlete cohort showed an
improvement in mean QD score to 9.9 (P ¼ .03 compared
with baseline). Of note, these nine patients who ultimately
improved without surgery and only with longer-term TOS-
speciﬁc PT had a shorter duration of symptomatology
before evaluation (3 months vs 15 months; P ¼ .006)
than those who had mild response to PT only and ulti-
mately underwent surgery and improved after.
Of all 27 nTOS athletes evaluated, 22 (81.5%) success-
fully returned to full activity at or above their previous
competitive level on their teams (Fig 3). The mean time
to pain-free return of the nTOS patients undergoing sur-
gery was 3.4 months, and the mean time to resumption
of full sport/activity was 4.4 months after surgery (range,
1-12 months). According to their late survey responses,
89% of the nTOS athletes who had operations would
choose surgery again.
Two athletes experienced symptomatic recurrence: one
volleyball player after 24 months, who then retired from
sport, and one after 6 months, from another shoulder pa-
thology that effectively ended their athletic careers. One
patient experienced entrapment of the supraspinatus nerve
Fig 2. Improvement in the 11-item version of the Disabilities of Arm, Shoulder and Hand (QuickDASH; QD) score
after treatment for neurogenic thoracic outlet syndrome (nTOS) in athletes.N/A, Not applicable; PT, physical therapy.
Fig 3. Percentage of athletes with neurogenic thoracic outlet
syndrome (nTOS) and Paget-Schroetter syndrome (PSS) that
returned to full athletic activity.
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resulted in retirement from collegiate swimming.
PSS patients. During the study period, 14 athletes un-
derwent treatment for PSS. All patients initially presented
with acute axillosubclavian vein thrombosis diagnosed on
duplex imaging. Thrombolysis was administered to all
but one patient (treated only with anticoagulation after
initial presentation) their preoperative evaluation (range,
1-60 days after diagnosis). Nine patients (64%) had com-
plete resolution of thrombus burden after thrombolysis,
and the remainder had persistent partial thrombus burden.
After initial anticoagulation/thrombolysis, all PSS athletes
underwent ﬁrst rib resection with subclavian vein venolysis,
with six (43%) undergoing venoplasty during their TOS
surgery to restore normal vein caliber and patency.All but one PSS patient returned to full athletic ability
(92.9% successful return to sport), with the mean pain-free
follow-up time of 1.9 months, and return to full athletic ac-
tivity at 4.7 months (range, 2-12 months; Fig 3; Table II).
Two patients experienced hemothorax requiring video-
assisted thoracoscopic surgical decompression. Subsequent
to these complications, we altered our algorithm by hold-
ing repeat anticoagulation until 5 to 7 days postoperatively.
Duration of postoperative anticoagulation averaged
2.3 months (range, 3 weeks-5 months).
On the long-term follow-up survey (mean, 34.5 months;
range, 13-144 months), all patients indicated they would
havedone the surgery again, and themeanQDscore (although
not calculated preoperatively for comparison) was 5.8.DISCUSSION
We have demonstrated in this series an 80% to 90% inci-
dence of return to sport within 4 to 5 months in competitive
athletes who presented with TOS and were aggressively
treated.Althoughneurogenic symptomsuntreated andundi-
agnosed can lead to nearly 1 year of disability from sport,
TOS-speciﬁc PT and, ultimately, surgery both resulted in
an81% likelihoodof return to sport. PSS athletes experienced
even better outcomes, with most presenting more acutely
and only 1 to 2 months of initial downtime, then 2 to
3 months postoperatively without pain, and 93% returning
to full athletic function. Althoughmany other factors beyond
the surgeon’s control dictate return tohigh school, collegiate,
or professional sports, we believe that the need for surgery for
TOS is not necessarily a career-ending diagnosis.
The careful selection of patients to undergo surgical
decompression for nTOS cannot be overemphasized. As
we reported previously,6 a highly selective algorithm consist-
ing of TOS-speciﬁc PT and offering surgery to those who
exhibit modest improvement increased our success rates
from 50% to 90%. It is no surprise that in this analysis, we
were able to achieve similar results by applying that same care-
ful algorithm to competitive athletes, with 81% returning to
JOURNAL OF VASCULAR SURGERY
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Although this somewhat counterintuitive algorithm discounts
those athletes in whom PT fails, our experience has been that
those patients do not improve dramatically with surgery.
Athletes in general present a challenging cohort to diag-
nose, and the delayed time of 11 months of symptoms seen
in this series before evaluation for a possible workup is likely
due to the extensive orthopedic workup from team physi-
cians, the use of other types of PT, and still a relative lack
of knowledge about TOS in general. The vigorous overhead
use of the upper extremities required in most overhead
sports predisposes high-performance athletes to a variety
of neurovascular injuries, particularly TOS.4 Outcomes of
athletes treated for TOS, particularly nTOS, have been
limited primarily to case reports and small series.10-17
The types of sport represented in our series are consistent
with those reported in the literature. Speciﬁcally, the prepon-
derance of baseball players, swimmers, rowers, and water
polo players is related to their primary arm motion, which
is related to arm abduction to 180, pulling the shoulders
down and back, or muscle swelling from trauma, exercise,
or hypertrophy of the trapezius, scalene muscles, or pector-
alis minor.18,19 Other reports have identiﬁed nTOS in tennis
players, weightlifters, football players, and wrestlers.14,20-22
With the same risk factors for nTOS, athletes that
develop PSS are in a high-risk cohort as a consequence of ex-
ertional activitywith the arm in elevation, combinedwith un-
derlying anatomic constraints at the level of the ﬁrst rib,
including hypertrophy of the underlying anterior scalene
muscle. The pathophysiology from the chronic overuse of
the upper extremity seen in athletes is related to initial posi-
tional injury to the subclavian vein that stimulates the forma-
tion of ﬁbrosis within and around the vein wall. Repetitive
cycles of injury and repair lead to the development of venous
collateral vessels along with constricting scar that gradually
narrows the subclavian vein. This process, which may occur
over many months to years and is particularly heightened
in the competitive athlete who has been playing his or her
entire life, is usually asymptomatic until clot forms.
Even if we accept that athletes are a special high-risk cate-
gory for TOS, there remains controversy about the surgical
therapy fornTOS.This is fueledby ratherpoor long-term func-
tional results for surgery, which likely stem from a number of
factors, including difﬁculty in diagnosis, lack of uniform indica-
tions, and lack of objective outcomesmetrics after surgery.23,24
Interestingly, we did ﬁnd a subset of athletes with
nTOS who had a modest improvement in their nTOS
symptoms after PT who were offered surgery but declined
and continued with PT. Seven of these nine patients (78%)
were able to return to their sport in long-term survey
follow-up, even though they had not undergone surgery.
This group, however, might be different. This nonopera-
tive cohort started with a lower QD baseline score and
had symptoms for a signiﬁcantly shorter period (3.0 months
vs 15.1 months), indicating they likely had a milder form of
nTOS. This ﬁnding that a shorter time of symptomatology
might respond to TOS-speciﬁc PT with excellent return to
sport highlights the importance of early recognition ofTOS in the athlete. Education of athletic trainers and the
sports medicine staff at the high school, collegiate, and pro-
fessional levels is an effort we are actively pursuing.
Another interesting ﬁnding is the continued improve-
ment in symptoms with time after surgery (Fig 2), as
shown by even lower QD scores on the follow-up survey.
We attribute this ﬁnding to the continued postoperative
conditioning and strengthening associated with training
and PT and to the makeup of these high-performance ath-
letes. This continued improvement long-term was not seen
in our prior publication.
Similarly, the shorter duration of symptoms as it relates
to long-term ability to return to sport might be a contrib-
uting factor for the PSS athletes doing so well after surgery.
Most athletes present with this issue acutely, and the mean
time to treatment of 1 to 2 months is typical with early
recognition of symptoms. Those athletes who received
prompt thrombolysis, clearance of the clot burden, and
expeditious surgical decompression were able to recover
relatively pain-free and return to their sport at full activity
within months. After our group had initially championed a
nonoperative role for certain PSS patients, we strongly
believe the young athlete who develops PSS must have sur-
gical decompression to maximize the likelihood to return to
sport without fear of recurrence or symptomatology.25-27
The only other major report of athletes with TOS is
from Washington University and describes outcomes in
32 athletes with PSS.5 Similar to our excellent results
with PSS patients, all 32 of their patients resumed unre-
stricted use of the upper extremity, with a median interval
of 3.5 months. They used a multidisciplinary approach
based on early diagnostic venography, thrombolysis, and
tertiary referral, paraclavicular thoracic outlet decompres-
sion with external venolysis, and frequent use of subclavian
vein reconstruction, and temporary postoperative anticoa-
gulation with or without an adjunctive arteriovenous ﬁstula.
The authors concluded that excellent outcomes could be
achieved, even for the challenging patient population of
athletes, by using a standardized multidisciplinary approach.
The best outcome in the care of competitive athletes
with all forms of TOS appears to require involvement of spe-
cialists in sports medicine, orthopedics, physical therapists,
team physicians, and individual athletic trainers. In treating
our cohort of athletes, we have adopted this approach,main-
taining close collaborations with our team physicians,
trainers, therapists, and sports medicine colleagues.
Our study has a number of limitations, as with all retro-
spective reviews. First, although some patients in the nTOS
cohort were nonoperative, it was not a true control group
becausewedidoffer them surgical intervention andobserved
that even without surgery, they improved at a very high rate
and returned to sport. Only a randomized trial could eluci-
date the true effect of longer regimens of PT, although likely
impractical given the nature of this patient cohort.
Second, along the lines of a lack of a control group for
the PSS patients, we have been aggressive about offering
young patients surgery based on our previous work,26,27
so again, there is the possibility that many of the PSS
JOURNAL OF VASCULAR SURGERY
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thrombolysis, without rib removal.
Finally, the ability of patients to recall many of the
timeline improvement issues on long-term survey phone
questionnaires is based on their recollections, and because
most of them did have a positive result, it is possible there
is bias in their answers. Fortunately, veriﬁcation of return to
sport was made more accurate by having box scores, re-
cords, and stories about these athletes, which we located
on the Internet or were provided by the teams/players.
Still, this is lacking objective testing of their overall return
to sport performance that could not be recorded.
CONCLUSIONS
We have documented favorable outcomes for treatment
of high-performance athletes who present with venous or
nTOS. Standardized treatment algorithms, prompt diag-
nosis and recognition, TOS-speciﬁc PT, and selective surgi-
calmanagement can lead to80% to90%of high-performance
athletes returning to their prior level of competitive sport.
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Submitted Jan 22, 2014; accepted Apr 4, 2014.DISCUSSIONDr Hugh A. Gelabert (Los Angeles, Calif). I thank the Soci-
ety for the honor of discussing this presentation. I thank the au-
thors for kindly providing me with their manuscript in a timely
manner so that I could review it.The authors have presented a series of thoracic outlet cases
which include both neurogenic and venous presentations. In all,
there were 27 neurogenic cases and 14 venous cases, for a total
of 41. Of the 27 neurogenic patients, 9 patients were managed
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ular decompression. Overall, 22 (81%) of the 27 returned to full
activity. On late follow-up, three athletes were disabled by late
recurrence resulting in a 66% return to competition rate. Of
note, all nine of the nonoperated patients improved although it
is not clear if they all returned to competition.
Of the 14 venous TOS patients,13 underwent thrombolysis,
9 (64%) had complete resolution of thrombus, and the remaining
4 (38%) had residual intravenous chronic thrombus. The report in-
dicates that 10 of the 14 patients underwent postdecompression
venogram and venoplasty (PTA). Ultimately 13 (92%) returned
to athletic competition.
This is a landmark report from our colleagues at Stanford, as
it represents the maturation of the TOS program in several ways.
They have continued with the use of physical therapy for selection
of neurogenic patients for surgical decompression. This is a unique
approach to neurogenic TOS. As previously presented to this soci-
ety, they identify those patients who improve with PT and select
them for surgical decompression. For most physicians treating
neurogenic TOS patients this was a counter intuitive approach.
In this iteration of their experience they reported on 9 patients
who improved with PT and did not require surgical decompres-
sion. This is an experience more in keeping with the mainstream
and might suggest a reversal in the current Stanford approach to
neurogenic TOS may be in the offering.
My ﬁrst question is whether you are reconsidering the use of a
positive response to physical therapy as a correct indication for sur-
gical decompression? With regard to the venous patients, the cur-
rent report represents an even more dramatic departure from past
protocol. The Stanford group has previously reported several series
that detail their management of venous TOS. Most notable
element was a highly selective approach to these patients. Theyreported at this meeting that only 45% of their venous TOS
patients ultimately required surgical decompression. In the current
manuscript, all venous TOS underwent surgical decompression.
This leads to my second question: what motivated this change
in approach? What is your current approach to selection of patients
with Paget Schroetter syndrome for surgical decompression?
The authors should be commended on a remarkable report.
They incorporates many of the most current approaches to man-
agement of these complex, difﬁcult problems and have achieved
excellent results. I enjoyed their manuscript and their presentation
and recommend it to you.
Dr Jason T. Lee. To answer your questions:
1. We continue to utilize response to PT as the main indicator for
offering surgery. While somewhat counterintuitive, this selects
out patients who are motivated, have resources and time to get
to PT (an important part of the postoperative phase), and sug-
gests that relief of the compression will have some positive
response. Even in the nine patients who improved on PT
and wound up not getting surgery, we did offer it to them,
and in fact their symptoms of onset was a much shorter time
period, perhaps suggesting they had a less severe form of
nTOS that did not ultimately require surgery for them to re-
turn to sport.
2. Selection of patients for vTOS decompression has undergone
an evolution at our institution as correctly pointed out by
Dr Gelabert. We continue to follow our recommendations
from our prior report in 2006 that those patients who were
younger (<28) and more athletic all should be offered rib
resection and venolysis, even with a perfect thrombolysis
outcome. We believe the recurrence rate (about 35% over
2 years) is too high for the young athlete to risk, so have become
more aggressive about rib resection after PS syndrome.
